Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20756860 | 0.89 | KCNH2 (0.37) | ESR1ESR2HRH1CYP2D6KCNH2 | |
| SCHEMBL20756924 | 0.89 | KAT2B (0.41) | GBA1KDM1AALDH1A1KDM2BKAT2B | |
| SCHEMBL19844789 | 0.89 | KAT2B (0.41) | GBA1KDM1AALDH1A1KDM2BKAT2B | |
| SCHEMBL19844788 | 0.89 | KAT2B (0.41) | GBA1KDM1AALDH1A1KDM2BKAT2B | |
| SCHEMBL9976591 | 0.89 | KDM1A (0.39) | GBA1KDM1AALDH1A1HRH1HSD11B1 | |
| SCHEMBL27051226 | 0.85 | KDM1A (0.41) | ESR1ESR2KDM1ACYP2D6CYP2C19 | |
| SCHEMBL19341335 | 0.84 | GBA1 (0.44) | GBA1CYP2D6HSD11B1KCNH2MAP3K12 | |
| SCHEMBL27055535 | 0.84 | CYP2D6 (0.48) | ESR1ESR2HRH1CYP2D6CYP2C19 | |
| SCHEMBL27345970 | 0.83 | GBA1 (0.33) | GBA1KDM1AALDH1A1HRH1CYP2D6 | |
| SCHEMBL26023067 | 0.82 | KDM1A (0.39) | KDM1AALDH1A1HRH1KDM2BKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-03-19 | — | — | US | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-2398797-B1 | PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-8569316-B2 | Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569316-B2 | Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8202887-B2 | 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors | JANSSEN R&D IRELAND (IE) | 2012-06-19 | — | — | US | disclosed |
| US-20120046270-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SPINT2, PEPD, DNPEP | GBA1 714/4885ESR1 2112/4885ESR2 3374/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | GBA1 444/4885ESR1 4389/4885ESR2 2959/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | GBA1 2394/4885ESR1 2101/4885ESR2 2104/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | GBA1 444/4885ESR1 4389/4885ESR2 2959/4885 |
| US-20200087296-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | GBA1 4262/4885ESR1 1438/4885ESR2 2980/4885 |
| US-20120046270-A1 | PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES | CDK2, ABL1, CDK1 | GBA1 2316/4885ESR1 1953/4885ESR2 3220/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | GBA1 4262/4885ESR1 1438/4885ESR2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.